FILPEGLA (Cipla Australia Pty Ltd)
Product name
FILPEGLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
Pegfilgrastim
Registration type
NCE/NBE
Indication
FILPEGLA is indicated for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and so reduce the incidence of infection, as manifested by febrile neutropenia.